🟢 Lantern Pharma is trading 7.3% up today on EMA trial clearance and AI spin-out launch

Lantern Pharma is trading 7.3% up today at $2.80 as investors react to the late-July EMA clearance for its LP-184 Phase 1b/2 trial and the launch of its AI spin-out.

• The company launched Open-Medicine AI on August 3 as a separate entity to commercialize its proprietary multi-agent AI co-scientist platform.
• The EMA clearance enables a Phase 1b/2 trial of lead drug candidate LP-184 for patients with advanced bladder cancer.
• The stock's performance aligns with a broader market rally, with major U.S. indices gaining over 1% on August 4, 2026.